Watson Pharmaceuticals announced that it has received approval from the FDA for its new six-month intramuscular formulation, Trelstar, a (triptorelin pamoate for injectable suspension) 22.5 mg. Trelstar 22.5 mg is a gonadotropin releasing hormone (GnRH) agonist used for the palliative treatment of advanced prostate cancer. […]
Hormone therapy (ADT), using luteinizing hormone releasing hormone (LHRH) agonists or gonadatropin releasing hormone or GnRH agonists (Lupron, Zoladex, Trelstar, Viadur, Vantas, Eligard and Synarel ) have been known to have many side effects, some severe and potentially life threatening. Many of us believe that ADT is associated with cardiovascular disease and diabetes along with [...]
I have just read a report from Mike Scott of a 64-year-old Croatian man who was recently diagnosed with advanced prostate cancer. His PSA was 21,380 ng/ml! Yes, I said a PSA of 21,380. Now, hold on to your seats for even more intriguing information. According to the report this man has never experienced any [...]
Watson Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Trelstar – 22.5 mg (triptorelin pamoate for injectable suspension) at a dosage which will be required only to be administered twice a year. […]
In a Town Hall discussion, “Ablating Testosterone in Prostate Cancer and the Concomitant Negative Effects”, Fred Saad, MD, FRCS, Director of Urologic Oncology, Professor of Surgery/Urology, U of M Chair in Prostate Cancer; University of Montreal discussed the negative effects that bone loss resulting from hormone therapy (ADT) poses to our life expectancy. His over [...]